ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO1343

Effect of Hemodialysis Vascular Access Type on Serum Interleukin-6 (IL-6) Levels in ESRD

Session Information

  • Vascular Access
    October 22, 2020 | Location: On-Demand
    Abstract Time: 10:00 AM - 12:00 PM

Category: Dialysis

  • 704 Dialysis: Vascular Access

Authors

  • Aggarwal (Gupta), Monika, Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States
  • Feldman, George M., Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States
  • Samuel, Naveen, Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States
  • Retnam, Reuben P., Virginia Commonwealth University, Richmond, Virginia, United States
  • Bandyopadhyay, Dipankar, Virginia Commonwealth University, Richmond, Virginia, United States
  • Ghosh, Shobha, Hunter Holmes McGuire VA Medical Center, Richmond, Virginia, United States
Background

Chronic inflammation is prevalent and associated with poor outcomes in end stage renal disease(ESRD),and may be related to underlying comorbid conditions like diabetes mellitus.It is unclear if dialysis vascular access type may affect inflammation. We evaluated the effect of hemodialysis vascular access type on serum IL-6 level.

Methods

15 patients with ESRD on chronic maintenance hemodialysis at McGuire Hunter Holmes VAMC were enrolled. Blood samples were drawn at 0 ,30, 60, 90, 120, 180, and 240 minutes after starting dialysis. Serum IL-6 was measured using ELISA.Data were analyzed using t-test and is presented as Mean+SD.

Results

6 patients had catheter (mean age 71.3+3.3 years), and 9 (mean age 64.5+4 years) had AV access . All were male. 5 patients in each group were African-American. 2 patients with catheter and 7 patients with AV access had diabetes.IL-6 level was higher at all time points(statistically significant) in patients with catheter compared to patients with AV access (Fig 1. and Table 1.)

Conclusion

ESRD patients with catheters had higher serum IL-6 levels compared to AV access inspite of lower proportion of diabetics. Catheters may contribute to inflammation, which may partly explain worse outcomes seen with catheters.

Table 1.IL-6 Level at different time points (Mean+/-SD)
Time Point (Minutes)AV accessCatheterP value
02.87+/-1.5311.96+/-9.470.009
302.1+/-1.1411.29+/-10.290.011
602.75+/-1.5311.6+/-8.920.004
903.15+/-1.5112.32+/-9.420.006
1203.14+/-1.6513.11+/-9.530.003
1803.32+/-1.5713.76+/-9.750.003
2403.27+/-1.2614.8+/-11.080.003

Fig1. IL-6 levels by Type of Vascular Access .

Funding

  • Veterans Affairs Support